RESEARCH BRIEF How can self-insured employers prepare for the portfolio impact of high-cost gene therapies coming to market? Self-insured employers currently rely on traditional stop-loss insurance to protect against unexpected … Read More
LEAPS Monthly Recap: April 2022
NEW MEMBER NEWDIGS welcomes Takeda Pharmaceuticals as a new collaborator in the LEAPS Project Takeda Pharmaceutical, a global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people … Read More
How can self-insured employers prepare for the portfolio impact of highcost gene therapies coming to market?
Self-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given that current approvals are in rare diseases, … Read More
FoCUS Monthly Recap: February 2022
JUST RELEASED Paying for Cures Toolkit updated with new pipeline modeling and financing strategies FoCUS released an updated and expanded version of its Paying for Cures Toolkit, which is designed to … Read More
LEAPS Monthly Recap: February 2022
WE’RE GROWING NEWDIGS searching for new director, program manager We’re searching for Director and Program manager talent—join our interdisciplinary think-and-do tank designing solutions to make biopharma and healthcare systems more … Read More
LEAPS leadership news: Kay Larholt retires, Fotios Kokkotos joins
In February 2022, Kay Larholt retired from her role as Director of Research for NEWDIGS, to stay on as a Senior Advisor. Fotios Kokkotos joined as NEWDIGS’ Director of Data … Read More
Broadly Engaged Team Science Comes to Life in a Design Lab
The objective of broadly engaged team science is to bring a diverse group of stakeholders into a project early and continue to include their expertise throughout to inform and propel … Read More
Data for modelling US projections of product approvals, patients treated, and product revenues for durable cell and gene therapies
Data in Brief, 41, 107891.Young, C. M., Trusheim, M., & Quinn, C. (2022). The recent marketing approval of several durable gene and cell therapies (2017-2020), together with observations that 7,000 … Read More
FoCUS Monthly Recap: January 2022
JUST RELEASED Paying for Cures Toolkit updated with new pipeline modeling and financing strategies Today FoCUS released an updated and expanded version of its Paying for Cures Toolkit, which is designed … Read More
LEAPS Monthly Recap: January 2022
RECENT PUBLICATION LEAPS research in Precision Reimbursement published in Clinical Pharmacology & Therapeutics The article, “Precision Reimbursement for Precision Medicine: Using Real-World Evidence to Evolve From Trial-and-Project to Track-and-Pay to Learn-and-Predict,” appeared … Read More